Nivalis Therapeutics, Inc. (ALPN) Rating Lowered to Strong Sell at ValuEngine

Nivalis Therapeutics, Inc. (NASDAQ:ALPN) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Ladenburg Thalmann Financial Services began coverage on shares of Nivalis Therapeutics in a research note on Thursday, July 27th. They set a “buy” rating and a $17.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $5.75.

Shares of Nivalis Therapeutics (NASDAQ:ALPN) opened at 11.69 on Wednesday. The company’s market cap is $7.79 million. Nivalis Therapeutics has a 52-week low of $7.20 and a 52-week high of $32.44. The stock’s 50 day moving average price is $8.80 and its 200-day moving average price is $9.71.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/nivalis-therapeutics-inc-alpn-rating-lowered-to-strong-sell-at-valuengine.html.

Nival

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Ladenburg Thalmann Financial Services began coverage on shares of Nivalis Therapeutics in a research note on Thursday, July 27th. They set a “buy” rating and a $17.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $5.75.

Shares of Nivalis Therapeutics (NASDAQ:ALPN) opened at 11.69 on Wednesday. The company’s market cap is $7.79 million. Nivalis Therapeutics has a 52-week low of $7.20 and a 52-week high of $32.44. The stock’s 50 day moving average price is $8.80 and its 200-day moving average price is $9.71.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/nivalis-therapeutics-inc-alpn-rating-lowered-to-strong-sell-at-valuengine.html.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply